Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer

Completed · Phase 2

Conditions studied: Kidney Cancer

In brief

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have metastatic renal cell cancer (kidney cancer) that is refractory to treatment with interleukin-2 or unable to be treated with interleukin-2.

Key facts

Study ID

NCT00057889

Run by

National Institutes of Health Clinical Center (CC)

Starts

2003-02-01

Expected to finish

2008-02-01

Last updated by the study team

2012-03-15

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.